dc.creator | Tobón C. | spa |
dc.creator | Pérez S. | spa |
dc.creator | Ugarte J.P. | spa |
dc.creator | Saiz J. | spa |
dc.date.accessioned | 2017-12-19T19:36:43Z | |
dc.date.available | 2017-12-19T19:36:43Z | |
dc.date.created | 2017 | |
dc.identifier.isbn | 9789811040856 | |
dc.identifier.issn | 16800737 | |
dc.identifier.uri | http://hdl.handle.net/11407/4275 | |
dc.description.abstract | Atrial fibrillation is the most common sustained cardiac arrhythmia. Dofetilide is an antiarrhythmic drug for the treatment of chronic AF that specifically blocks the rapid component of the delayed rectifier potassium current IKr. Dofetilide prolongs the action potential duration and QT interval in a concentration-dependent fashion, therefore, the risk of QT prolongation is dose related. It is important to study the electrophysiological effects of dofetilide at different concentrations in human atrial cells. For this, we simulated the effects of dofetilide on human atrial cell and studied its effect on atrial action potential under normal conditions and during cAF. We developed a model of dofetilide effects on IKrand IKACh. Our results show that dofetilide blocks both currents in a fraction greater as the concentration increases, which results in an action potential duration lengthening. To our knowledge, this is the first work that has developed mathematical models of dofetilide effects on IKrand IKAChcurrents to study its effect on human atrial action potential. © Springer Nature Singapore Pte Ltd. 2017. | eng |
dc.language.iso | eng | |
dc.publisher | Springer Verlag | spa |
dc.relation.isversionof | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018409745&doi=10.1007%2f978-981-10-4086-3_10&partnerID=40&md5=280d9472ab3c08a89e7be6b0469e002e | spa |
dc.source | Scopus | spa |
dc.title | Dofetilide effect on human atrial action potential under normal and atrial fibrillation conditions. In silico study | spa |
dc.type | Conference Paper | eng |
dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | |
dc.contributor.affiliation | Tobón, C., MATBIOM, Universidad de Medellín, Medellín, Colombia | spa |
dc.contributor.affiliation | Pérez, S., Grupo de Dinámica Cardiovascular, Universidad Pontificia Bolivariana, Medellín, Colombia | spa |
dc.contributor.affiliation | Ugarte, J.P., Grupo de Dinámica Cardiovascular, Universidad Pontificia Bolivariana, Medellín, Colombia | spa |
dc.contributor.affiliation | Saiz, J., CI2B, Universitat Politècnica de València, Valencia, Spain | spa |
dc.identifier.doi | 10.1007/978-981-10-4086-3_10 | |
dc.subject.keyword | Antiarrhythmic drug | eng |
dc.subject.keyword | Atrial fibrillation | eng |
dc.subject.keyword | Dofetilide | eng |
dc.subject.keyword | In silico model | eng |
dc.subject.keyword | Biomedical engineering | eng |
dc.subject.keyword | Electric rectifiers | eng |
dc.subject.keyword | Electrophysiology | eng |
dc.subject.keyword | Action potential durations | eng |
dc.subject.keyword | Antiarrhythmic drug | eng |
dc.subject.keyword | Atrial fibrillation | eng |
dc.subject.keyword | Cardiac arrhythmia | eng |
dc.subject.keyword | Concentration-dependent | eng |
dc.subject.keyword | Dofetilide | eng |
dc.subject.keyword | In-silico models | eng |
dc.subject.keyword | Potassium currents | eng |
dc.subject.keyword | Diseases | eng |
dc.publisher.faculty | Facultad de Ciencias Básicas | spa |
dc.abstract | Atrial fibrillation is the most common sustained cardiac arrhythmia. Dofetilide is an antiarrhythmic drug for the treatment of chronic AF that specifically blocks the rapid component of the delayed rectifier potassium current IKr. Dofetilide prolongs the action potential duration and QT interval in a concentration-dependent fashion, therefore, the risk of QT prolongation is dose related. It is important to study the electrophysiological effects of dofetilide at different concentrations in human atrial cells. For this, we simulated the effects of dofetilide on human atrial cell and studied its effect on atrial action potential under normal conditions and during cAF. We developed a model of dofetilide effects on IKrand IKACh. Our results show that dofetilide blocks both currents in a fraction greater as the concentration increases, which results in an action potential duration lengthening. To our knowledge, this is the first work that has developed mathematical models of dofetilide effects on IKrand IKAChcurrents to study its effect on human atrial action potential. © Springer Nature Singapore Pte Ltd. 2017. | eng |
dc.creator.affiliation | MATBIOM, Universidad de Medellín, Medellín, Colombia | spa |
dc.creator.affiliation | Grupo de Dinámica Cardiovascular, Universidad Pontificia Bolivariana, Medellín, Colombia | spa |
dc.creator.affiliation | CI2B, Universitat Politècnica de València, Valencia, Spain | spa |
dc.relation.ispartofes | IFMBE Proceedings | spa |
dc.relation.ispartofes | IFMBE Proceedings Volume 60, 2017, Pages 38-41 | spa |
dc.relation.references | Aliot, E., Haissaguerre, M., & Jackman, W. (2008). Catheter Ablation of Atrial Fibrillation | spa |
dc.relation.references | Courtemanche, M., Ramirez, R. J., & Nattel, S. (1998). Ionic mechanisms underlying human atrial action potential properties: Insights from a mathematical model. American Journal of Physiology - Heart and Circulatory Physiology, 275(1 44-1), H301-H321. | spa |
dc.relation.references | Courtemanche, M., Ramirez, R. J., & Nattel, S. (1999). Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: Insights from a mathematical model. Cardiovascular Research, 42(2), 477-489. doi:10.1016/S0008-6363(99)00034-6 | spa |
dc.relation.references | Ficker, E., Jarolimek, W., Johann, K., Baumann, A., & Brown, A. M. (1998). Molecular determinants of dofetilide block of HERG K+ channels. Circulation Research, 82(3), 386-395. | spa |
dc.relation.references | Goralnick, E., & Bontempo, L. J. (2015). Atrial fibrillation. Emergency Medicine Clinics of North America, 33(3), 597-612. doi:10.1016/j.emc.2015.04.008 | spa |
dc.relation.references | Jaiswal, A., & Goldbarg, S. (2014). Dofetilide induced torsade de pointes: Mechanism, risk factors and management strategies. Indian Heart Journal, 66(6), 640-648. doi:10.1016/j.ihj.2013.12.021 | spa |
dc.relation.references | January, C. T., Wann, L. S., & Alpert, J. S. (2014). AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the american college of Cardiology/American heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol, 212. | spa |
dc.relation.references | Jurkiewicz, N. K., & Sanguinetti, M. C. (1993). Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circulation Research, 72(1), 75-83. | spa |
dc.relation.references | Kneller, J., Zou, R., Vigmond, E. J., Wang, Z., Leon, L. J., & Nattel, S. (2002). Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circulation Research, 90(9), E73-87. | spa |
dc.relation.references | Lauer, M. R. (2001). Dofetilide: Is the treatment worse than the disease? Journal of the American College of Cardiology, 37(4), 1106-1110. doi:10.1016/S0735-1097(01)01146-9 | spa |
dc.relation.references | Ohler, A., Amos, G. J., Wettwer, E., & Ravens, U. (1994). Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: No evidence for "reverse use dependent" block. Naunyn-Schmiedeberg's Archives of Pharmacology, 349(6), 602-610. doi:10.1007/BF01258466 | spa |
dc.relation.references | Saiz, J., Ferrero Jr., J. M., Monserrat, M., Gomis-Tena, J., Chorro, J., & Ferrero, A. (2003). Effects of the antiarrhythmic drug dofetilide on myocardial electrical activity: A computer modelling study. Paper presented at the Computers in Cardiology, 30 291-294. | spa |
dc.relation.references | Tande, P. M., Bjørnstad, H., Yang, T., & Refsum, H. (1990). Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel IK blocking drug, UK-68,798: Potent in guinea pig but no effect in rat myocardium. Journal of Cardiovascular Pharmacology, 16(3), 401-410. | spa |
dc.relation.references | Van Wagoner, D. R. (2003). Electrophysiological remodeling in human atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 26(7 II), 1572-1575. | spa |
dc.relation.references | Voigt, N., Rozmaritsa, N., Trausch, A., Zimniak, T., Christ, T., Wettwer, E., . . . Ravens, U. (2010). Inhibition of IK,ACh current may contribute to clinical efficacy of class i and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn-Schmiedeberg's Archives of Pharmacology, 381(3), 251-259. doi:10.1007/s00210-009-0452-6 | spa |
dc.relation.references | Zimetbaum, P. (2012). Antiarrhythmic drug therapy for atrial fibrillation. Circulation, 125(2), 381-389. doi:10.1161/CIRCULATIONAHA.111.019927 | spa |
dc.relation.references | Zipes, D. P., & Jalife, J. (1995). Cardiac Electrophysiology: From Cell to Bedside. | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | |
dc.type.driver | info:eu-repo/semantics/conferenceObject | |
dc.identifier.reponame | reponame:Repositorio Institucional Universidad de Medellín | spa |
dc.identifier.instname | instname:Universidad de Medellín | spa |